UK's Advisory Council seeks evidence on medical cannabis impact

📢 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁: The UK's Advisory Council on the Misuse of Drugs (AMCD) has now officially commenced its review of the legislation that allowed medical cannabis access, and has published an open call for evidence. The main objectives of this review are to: 1) Consider whether the legislation had the intended impact 2) Identify any unintended consequences 3) Make recommendations on how to mitigate 2) above This is the government's first proper assessment of the law from 2018, so its importance cannot be overstated. 🇬🇧 Anyone involved in the UK industry - as a prescriber, importer, manufacturer, individual patient or researcher - should ensure they submit a response by the deadline of 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟳. The link to the ACMD's call for evidence is below 👇

Less bureaucracy in medical cannabis. More time for care? The requirement for doctors to regularly report individual medical-cannabis treatment outcomes to the state has been abolished. What changes now? Doctors no longer have to submit annual summaries of “treatment outcomes” for each patient. The system returns to standard clinical and pharmacovigilance procedures. In practice, this means fewer forms and faster access to therapy for appropriately indicated patients. The exceptional monitoring made sense in the early phase of introducing medical cannabis. Today it is replaced by longer clinical experience and a clearer indication framework. The administrative relief frees capacity where it belongs, with the patient. #MedicalCannabis #CzechRepublic #HealthcarePolicy #SUKL #CannabisIndustry

California Governor Gavin Newsom has vetoed AB 1332, legislation that would have allowed certain cannabis microbusinesses to ship medical products directly to patients. The bill, aimed at expanding access for patients struggling to find specialised products locally, faced rejection due to concerns over administrative complexity, high costs, and limitations in the Track-and-Trace system. While Newsom expressed openness to future solutions, medical cannabis access in California continues to face challenges. Sales have dropped from approximately $540 million in 2021 to a projected $200 million in 2025, driven by regulatory burdens, taxation, and prioritisation of adult-use products. Advocates warn that patients in many regions remain underserved despite early legalisation efforts. How can California balance patient access with regulatory oversight to support its medical cannabis market?

Are you up to date on the new crackdown on medical cannabis in NSW? Here’s what patients and professionals need to know. Significant policy changes in New South Wales are reshaping how medical cannabis is prescribed and accessed. These updated regulations affect both healthcare professionals and patients alike, introducing stricter requirements and more rigorous oversight. Many in the industry are already seeing the impacts, particularly on the availability of prescribed cannabis products. Staying informed on these evolving policies is crucial for maintaining compliance and ensuring patient care standards are met. Read the full report on our site and share your insights with us. #cannabis #news #trending #NSW #medicalcannabis #regulations

This week's Baystate Report for Cannabis Coast to Coast is live now over at Pro Cannabis Media! I talk about the newest delay in social consumption guidance and the State's step towards opening up the current medical cannabis delivery framework. Watch below: https://lnkd.in/eytQDSPP #Industry #Regulation #NationalNews #RegionalNews #B2B #Massachusetts #USA

Patient groups urge U.K.’s antitrust regulator to investigate drugmakers for “suspected” and “coordinated” efforts to drive up the prices of medicines. https://trib.al/gIJg29a

In a historic move, Spain’s Council of Ministers has approved a long-awaited Royal Decree regulating the medicinal use of cannabis preparations in hospital settings. Following years of advocacy on behalf of patients and campaigners, the decision marks a decisive step toward the integration of medical cannabis into the country’s healthcare system. The new framework, proposed by the Ministry of Health, establishes the conditions for the prescription of ‘standardised master formulas’ made from cannabis preparations, by specialist physicians in hospital settings. The regulations extend to the prescription of cannabis-based oils only, and do not permit the use of cannabis flower. Read the full article here 🔗 https://lnkd.in/ek4624qd

✂️ Cutting red tape in Canada’s health sector. Health Canada and the Public Health Agency of Canada have announced 42 initiatives aimed at reducing regulatory burden across foods, drugs, medical devices, cannabis, and more. With consultations planned, now is the time for the industry to weigh in. Learn more: https://gowlg.co/4pMOF6n William Bjornsson, Alex Camenzind, Alex Gloor, Lewis Retik | #HealthCanada #LifeSciences #RegulatoryCompliance

Cutting through the red tape! Health Canada’s Red Tape Reduction Report could make life easier for U.S. exporters—streamlining approvals, reducing testing, and simplifying registration for drugs, medical devices, and health products. Now’s the time to see how it could impact your Canadian business and make your voice heard. #RedTapeReduction #HealthCanada #RegulatoryReform #USCanadaTrade #LifeSciences #MarketAccess

Nebraska’s latest policy debate over medical cannabis regulations is gaining attention across the healthcare and regulatory landscape. Discover what these developments could mean for both the industry and patients. The debate around medical cannabis regulations in Nebraska is intensifying as lawmakers challenge existing frameworks. Recent discussions have highlighted the urgent need for clarity and alignment between patient needs and legal structures. Stakeholders across the state are watching closely, recognizing the potential for new policies to impact healthcare access and the overall cannabis market. These legislative moves could set important precedents for neighboring states and industry professionals alike. This ongoing dialogue demonstrates the complexities of cannabis regulation and the significant effects policy decisions can have on both patients and providers. Read the full report on our site and share your insights with us. #cannabis #news #Nebraska #medicalcannabis #industry #regulations #trending